SUSAN HILSENBECK to Adult
This is a "connection" page, showing publications SUSAN HILSENBECK has written about Adult.
Connection Strength
0.408
-
To share or not to share: a randomized trial of consent for data sharing in genome research. Genet Med. 2011 Nov; 13(11):948-55.
Score: 0.022
-
Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth. 2009; 9(6-7):3-10.
Score: 0.018
-
Isolation of the ocular surface to treat dysfunctional tear syndrome associated with computer use. Ocul Surf. 2007 Oct; 5(4):308-15.
Score: 0.017
-
Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005 Jan; 89(2):173-8.
Score: 0.014
-
Gambian Mothers Lack Obstetric Danger Sign Knowledge, But Educational Intervention Shows Promise. Ann Glob Health. 2024; 90(1):31.
Score: 0.013
-
Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. Clin Colorectal Cancer. 2020 06; 19(2):e49-e57.
Score: 0.010
-
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.
Score: 0.010
-
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
Score: 0.010
-
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435.
Score: 0.010
-
A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities. Cancer Chemother Pharmacol. 2019 02; 83(2):349-360.
Score: 0.009
-
Exome sequencing disclosures in pediatric cancer care: Patterns of communication among oncologists, genetic counselors, and parents. Patient Educ Couns. 2019 04; 102(4):680-686.
Score: 0.009
-
Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.
Score: 0.009
-
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
Score: 0.009
-
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017 Nov; 166(1):277-287.
Score: 0.008
-
Retrospective review of genomic testing in breast cancer: Does it improve outcome? Breast Cancer Res Treat. 2017 May; 163(1):191-195.
Score: 0.008
-
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 02 14; 317(6):596-605.
Score: 0.008
-
Stereotactic Biopsy of Segmental Breast Calcifications: Is Sampling of Anterior and Posterior Components Necessary? Acad Radiol. 2016 06; 23(6):682-6.
Score: 0.008
-
The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia. PLoS One. 2015; 10(7):e0132214.
Score: 0.007
-
Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.
Score: 0.007
-
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1688-98.
Score: 0.007
-
Pediatric data sharing in genomic research: attitudes and preferences of parents. Pediatrics. 2014 Apr; 133(4):690-7.
Score: 0.007
-
Participants' recall and understanding of genomic research and large-scale data sharing. J Empir Res Hum Res Ethics. 2013 Oct; 8(4):42-52.
Score: 0.006
-
Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol. 1993 Aug; 16(4):301-9.
Score: 0.006
-
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
Score: 0.006
-
Estimation of completeness and adjustment of age-specific and age-standardized incidence rates. Biometrics. 1992 Dec; 48(4):1249-62.
Score: 0.006
-
The increasing recognition of adenosquamous lung carcinoma (1977-1986). Am J Clin Oncol. 1992 Aug; 15(4):356-62.
Score: 0.006
-
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer. 2012 Jun 13; 12:243.
Score: 0.006
-
The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol. 1992 May; 45(2):142-6.
Score: 0.006
-
Balancing the risks and benefits of genomic data sharing: genome research participants' perspectives. Public Health Genomics. 2012; 15(2):106-14.
Score: 0.006
-
Assessment of the learning curve for pancreaticoduodenectomy. Am J Surg. 2012 Jun; 203(6):684-90.
Score: 0.006
-
Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat. 2011 Aug; 129(1):221-7.
Score: 0.005
-
Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011 Jun 15; 17(12):4177-86.
Score: 0.005
-
The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):463-72.
Score: 0.005
-
Long-term survival in stage III and IV ovarian cancer. Arch Gynecol Obstet. 1991; 249(2):87-93.
Score: 0.005
-
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011 Jan 10; 29(2):166-73.
Score: 0.005
-
Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010 Nov 01; 70(21):8517-25.
Score: 0.005
-
Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2010 05 15; 160(2):268-76.
Score: 0.005
-
Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009 Nov 12; 2:47.
Score: 0.005
-
Pharmacogenetics of breast cancer: toward the individualization of therapy. Cancer Invest. 2009 Aug; 27(7):699-703.
Score: 0.005
-
Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2009 Oct; 156(2):189-98.
Score: 0.005
-
Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008 May; 247(5):732-8.
Score: 0.004
-
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 07; 100(9):672-9.
Score: 0.004
-
Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res. 2007 Jun 01; 13(11):3235-43.
Score: 0.004
-
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.
Score: 0.004
-
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.
Score: 0.004
-
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005 Feb 20; 23(6):1169-77.
Score: 0.004
-
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
Score: 0.004
-
Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
Score: 0.003
-
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003 Dec; 4(5):348-53.
Score: 0.003
-
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 02; 362(9381):362-9.
Score: 0.003
-
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 01; 20(11):2701-12.
Score: 0.003
-
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res. 2001 Jun; 7(6):1739-42.
Score: 0.003
-
Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol. 2000 May; 18(9):1906-13.
Score: 0.003
-
Laparoscopic cholecystectomy and cirrhosis: a case-control study of outcomes. Liver Transpl. 2000 May; 6(3):340-4.
Score: 0.003
-
Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. Am J Med Genet. 1999 Aug 27; 85(5):455-62.
Score: 0.002
-
A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med. 1998 Jul; 105(1):7-11.
Score: 0.002
-
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.
Score: 0.002
-
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood. 1998 Mar 01; 91(5):1533-41.
Score: 0.002
-
A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Invest New Drugs. 1998; 16(1):57-67.
Score: 0.002
-
Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett. 1997 Jun 24; 116(2):177-83.
Score: 0.002
-
Preoperative spirometry and laparotomy: blowing away dollars. Chest. 1997 Jun; 111(6):1536-41.
Score: 0.002
-
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs. 1997; 15(4):361-4.
Score: 0.002
-
Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60.
Score: 0.002
-
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
Score: 0.002
-
Signs of temporomandibular disorders in patients with horizontal mandibular deficiency. J Orofac Pain. 1996; 10(1):21-7.
Score: 0.002
-
Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer. 1995 Nov 15; 76(10 Suppl):1978-86.
Score: 0.002
-
Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993 Nov; 11(11):2194-204.
Score: 0.002
-
Optimal mastectomy timing. J Natl Cancer Inst. 1992 Mar 04; 84(5):346-8.
Score: 0.001
-
Five-drug antiemetic combination for cisplatin chemotherapy. Cancer Invest. 1992; 10(3):191-9.
Score: 0.001
-
Lung carcinoma in 1,336 patients. Am J Clin Oncol. 1991 Dec; 14(6):496-508.
Score: 0.001
-
Comparative efficacy of short-term versus long-term cefoxitin prophylaxis against postoperative infection after radical hysterectomy: a prospective study. Obstet Gynecol. 1991 May; 77(5):729-34.
Score: 0.001
-
Toxicity of FED chemotherapy in non-small-cell lung cancer. Am J Clin Oncol. 1987 Dec; 10(6):499-506.
Score: 0.001
-
Cancer among Haitians in Florida. Cancer. 1987 Jan 01; 59(1):184-8.
Score: 0.001
-
Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer. Breast Cancer Res Treat. 1984; 4(4):283-8.
Score: 0.001